Drugs / Triphasil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00236795 | Jan 1997 → Mar 1999 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT02404038 Comparator | Jul 2015 → Jul 2017 | HIV infectious disease | Desmond Tutu HIV Centre | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Triphasil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02404038 ↗ |
| Route | Oral | “A Triphasil pill is taken for 28 consecutive days at the same time each day.” NCT00236795 ↗ |